Nipocalimab demonstrated significant efficacy in moderate-to-severe Sjögren’s disease in phase 2 trial
A new study published in The Lancet has found that nipocalimab, a neonatal Fc receptor (FcRn) blocker, significantly reduces clinical disease activity in patients with …